BRUPHARM PHARMALAB
ActiveSummary
The computed 12-month bankruptcy probability of BRUPHARM PHARMALAB is 5.6% (elevated). The 2025 annual accounts show negative equity (-€102,855) and a net result of €10,043. Equity is shrinking by about 55% per year across the filed financial years. Its solvency ranks better than 8% of 9,778 sector peers (NACE 46, financial year 2025). The company has been active since 2022 and the Belgian Official Gazette contains no insolvency signals. The KBO does carry 1 administrative register entry (see administrative flags).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
30-09
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format · 61 days late
2025
31-12
Financial
Back to profitnet €10,043
Net result €10,043 after 3 loss-making years.
07-11
NBB filing
Annual accounts filed
financial year 2024 · micro format · 99 days late
07-11
NBB filing
Annual accounts filed
financial year 2023 · micro format · 464 days late
2024
18-04
NBB filing
Annual accounts filed
financial year 2022 · micro format · 262 days late
12-04
KBO administration
UBO non-compliance
event 01-04-2024
2023
31-12
Financial
Weakest financial yearnet -€112,709
Net result drops to -€112,709, the lowest in the series; recovery starts the following year.
SignalFinancial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 1 deed read
About the unread acts
We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.